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ABStRACt
To mitigate medical risks in remote environments, the authors have implemented an innovative integra-
ted medical support solution for bleeding management on board ships since 2013. Fresh whole blood 
transfusion (FWBT) and lyophilised plasma were put in place to address life threatening haemorrhages 
in maritime operations in the Arctic and Antarctica. The authors are illustrating the bleeding risks with an 
actual case occurring in Antarctica prior to the implementation of these procedures. They are presenting 
the different steps involved in the complex process of FWBT, from blood donors’ qualifications to actual 
transfusions. The pros and cons of blood transfusion in extreme remote environment are discussed, inclu-
ding the training of health care professionals, equipment requirements, legal and ethical issues, decision 
making in complex blood group matching, medical benefits and risks. 
(Int Marit Health 2016; 67, 2: 79–82)
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INtRODUCtION
In our maritime medical support experience in the Kara 
Sea, the north-eastern Barents Sea, and near the Antarctic 
Peninsula, air medevac was most of the time not possible 
and even if it was possible it required from 2 to 5 sailing 
days, this could have been delayed even more due to weath-
er conditions, known to change very rapidly in the Arctic area 
or in the Drake Passage. 
To mitigate medical risks in these challenging environ-
ments, the authors have implemented an innovative inte-
grated medical support solution on board seismic vessels 
(oil and gas surveys) since 2013 and Expedition Cruise 
vessels since 2015.
Many medevacs are conducted for suspected emergen-
cies when clinically in doubt or if further medical examina-
tion is needed. Therefore, we first emphasized the upgrade 
of diagnostic tools to help identify and anticipate onboard 
emergency cases. The diagnostic equipment, including mo-
bile X-ray, portable ultrasound, mobile slit lamp, point of care 
automated laboratory systems, were used by a specifically 
trained medical team consisting of an emergency physician 
and a registered nurse backed up by an adapted 24/7 top 
side support ashore.
Therapeutic tools were also upgraded and the most 
dramatic and innovative improvement was the implemen-
tation of fresh whole blood transfusion (FWBT) and lyoph-
ilised plasma to address trauma-induced life threatening 
haemorrhages and slow uncontrolled bleedings of medical 
origin (mostly gastrointestinal). These procedures were the 
only alternative in a remote environment where there is no 
access to certified blood products, because maintaining 
a blood bank would be both operationally difficult due to 
the short shelf life of blood products, most of them would 
expire on board, and also unethical due to the scarcity of 
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blood products in general. Kauvar et al. [1] reported an 87% 
to 94% wastage rate for Packed Red Blood Cells in Forward 
Surgical Teams actively engaged in support of combat op-
erations, and we could expect a much higher wastage rate 
in commercial maritime operations.
ILLUStRAtION: BLEEDING CASE  
IN ANtARCtICA
On December 6th, 2014, on an expedition cruise vessel, 
sailing near the Antarctica Peninsula, a 30-year-old male 
seafarer was admitted to the ship hospital at 2.00 AM for 
feeling faint with brief loss of consciousness. He reported 
a history of peptic ulcer, no current medical treatment nor 
over the counter drug use; he consumed alcohol on a daily 
basis but did not smoke. He reported dizziness for the last 
3 days, dull epigastric pain partially relieved by food intake 
and red blood in his stools. 
While walking to the exam couch, he briefly fainted 
again with a 20 s loss of consciousness as observed by the 
medical team. Vital signs were within normal limits (blood 
pressure [BP] 100/80 mm Hg, heart rate [HR] 100 bpm, 
respiratory rate [RR] 18 bpm, and peripheral capillary oxygen 
saturation [SpO2] 99%), blood glucose 145 mg/dL, haemo-
globin 11 g/dL, exhaled breath was negative for alcohol, 
electrocardiogram within normal limits and the only clinical 
finding was red blood on digital rectal exam. A pantoprazole 
IV administration was initiated and the patient remained 
stable until 6.30 AM when he started to feel weaker with 
foul rectal bleeding and at 8.30 AM he fainted again with 
a 30 s loss of consciousness, his haemoglobin dropping to 
8.7 g/dL, IV tranexamic acid was administered. Top side 
support was called and medevac was triggered. Initially no 
plane was available and the medevac was to be conducted 
by sailing back to Ushuaia, a 2 days trip, which was unlikely 
to bring back alive the patient without finding an effective 
way to stop the bleeding or compensate the loss of blood. 
Unexpectedly, a plane engaged on another medevac ashore 
was localized in a nearby Chilean station in King George 
Island and the patient, still stable (HR 120, BP 105/50), was 
transported by a zodiac ashore at 3.30 PM, transferred to an 
Argentinian C130 Hercules which took off at 4.30 PM, and 
landed in Rio Gallegos, Argentina, at 7.00 PM. Rushed to the 
local hospital, the patient decompensated in haemorrhagic 
shock and required endotracheal intubation, vasoactive 
amines were administered, haemoglobin had dropped to 
7 g/dL. The patient was hospitalised in the intensive care 
unit, his acute bleeding peptic ulcer benefitted from the 
transfusion of 3 units of red blood cells, gastric endoscopy 
was performed and the patient was discharged a  week 
later. If this miraculous medevac plane had not been there, 
chance of survival with a 2 days medevac by sea was very 
slim without blood products.
FRESH WHOLE BLOOD tRANSFUSION  
AND LYOPHILISED PLASMA
tHE RISKS
Managing a severe bleeding without blood bank is in-
deed a critical challenge. Acute haemorrhage from trauma 
or slow uncontrolled bleeding will lead to death if the cause 
of bleeding is not managed properly and the blood loss not 
compensated when getting below vital threshold. Stopping 
a bleeding may require, depending on the cause, sophisti-
cated techniques, from damage control surgery (i.e. spleen 
fracture, liver wound), colonoscopy or gastroscopy (i.e. gas-
tric ulcer, diverticulosis, etc.) to embolisation (i.e. pelvic 
fracture, posterior epistaxis, etc.) and specialised healthcare 
providers who are not easily deployable in a remote setting.
Also, in some places (tropical, sub-tropical, low level of care), 
local hospitals are capable of providing blood products but with 
a level of safety in regard to infectious agents way below stan-
dards of high income or less exposed countries which implies 
to reconsider the benefit/risk ratio for local blood transfusion.
Finally, with the development of Expedition Cruises with 
thousands of passengers sailing in the Polar Regions, some 
of them on anticoagulant prescription, the risk of severe 
bleeding of medical origin is more potent.
Massive blood loss will deplete the platelets and clotting 
factors, causing more bleeding, this coagulopathy is aggra-
vated by hypothermia and acidosis, commonly observed 
in shocks, which are part of the “trauma triad of death”. 
Therefore when life threatening bleeding occurs, blood prod-
ucts are critical. For resuscitation cases requiring massive 
transfusion, FWB is also more potent than the combination 
of packed red blood cells (RBC), platelets and fresh frozen 
plasma (FFP), with a better outcome for the patient [2–4]. 
This excellent potency is most probably due to the perfect 
1/1/1 ratio for plasma, red cells and platelets, the low dose 
of conservative additives and anticoagulants compare to 
units of blood bank products, and not using large amounts 
of RBC older than 14 days since storage time affects quality 
of cells [5]. A 500 mL warm FWB unit provides all blood 
components, including coagulation factors, unaltered and 
in right proportion and temperature (haematocrit 38–50%, 
150,000–400,000 platelets per microliter, and 100% ac-
tivity of clotting factors) compare to the 660 mL of a mix 
of 1 unit of RBC, with 1 unit of FFP, and 1 unit of platelet 
concentrate with a whole haematocrit of 29%, 88,000 plate-
lets per microliter, and 65% coagulation factor activity [1].
This “haemorrhage damage control” process was adapt-
ed from military medical practice. FWBT has been used 
extensively to resuscitate casualties in military conflicts 
since World War I, but was discontinued in the 1980’s with 
the occurrence of human immunodeficiency virus (HIV). 
Prior to HIV, the balance of a low risk of transmission of an 
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infectious agent (usually syphilis, hepatitis), often treatable 
and not deadly in short term, was overcome by the benefit 
of saving a dying bleeding patient.
tHE MItIGAtION MEASURES
Since the wars in Afghanistan and Iraq the FWBT process 
was implemented again with an upgraded screening tech-
nique which lowers the risk of transmission of an infectious 
agent, and as Kauvar et al. [1] stated “FWBT is convenient, 
safe, and effective in certain military situations”. This on-
site screening of collected FWB units with the use of rapid 
detection tests for HIV, HCV, and HBV was recommended 
by Spinella et al. [5] as a standard process to minimize the 
risk of infectious agent transmission. 
According to the French Military Blood Transfusion Cen-
tre, the residual infectious risk of transmitting an infection is 
estimated at approximately 0.00005 per FWB unit in French 
Military overseas operations where FWBT is implement-
ed. Indeed, at the time of collection, all French military 
volunteer donors undergo standard risk questionnaire 
screening and are tested for HIV, hepatitis B virus (HBV), 
and hepatitis C virus (HCV). The residual risk is for human 
lymphotropic virus (HTLV) because currently there is no 
screening test for this virus usable before transfusion. 
The questionnaire screening must eliminate the donors 
coming from endemic areas (Intertropical Africa, Caribbean, 
Guyana) if they have not been tested before for this virus (i.e. 
regular donor). Bacterial contamination of FWB is a risk under 
field conditions but is limited by short storage period — only 
6 h at room temperature. 
These risks must be compared with a life threatening 
bleeding when neither certified Blood Bank products are 
available nor effective control of bleeding through surgery, 
endoscopy or endovascular embolisation is possible, leading 
to certain death. Still, even with a beneficial survival bal-
ance, due to these residual risks, FWBT is not approved by 
Food and Drug Administration nor other Civilian Health agen-
cies for routine use, but it is approved by NATO (STANAG 
2939 edition 5, 2010 Minimum Requirements for Blood, 
Blood Donors, and Associated Equipment). It is implemented 
by waiver only when no other alternative is available to save 
the life of a critically bleeding patient and a record of the 
decision process is kept.
The drawback of FWBT is that it is safer to use matching 
ABO blood type, therefore it is important to recruit enough 
volunteers to cover the whole spectrum of ABO blood types. 
To do so we organised among the oil and gas pro-
fessional crews an agile and customised prescreening 
process of volunteer blood donors on board and at sea 
in order to facilitate the process by reducing the amount 
of time the volunteers are required to dedicate to FWB 
collection process. 
The onboard prescreening protocol included the fol-
lowing steps:
 — on board lectures to the whole crew to explain the ben-
efits and the rationale of volunteering for FWBT in order 
to recruit as many volunteer blood donors as possible;
 — on board medical interviews to screen for low-risk volun-
teer donors according to recognised medical consensus 
on Go and No Go parameters, based on medical history, 
exposure to infectious agents, etc.;
 — on board blood sampling for medically screened vol-
unteers with centrifugation of blood samples prior to 
shipping to a certified laboratory for biological screening 
and blood typing. Biological screening included test for 
HIV, HTLV, hepatitis B and C, and syphilis. Results were 
kept confidential and managed directly with patient 
and his/her family physician; occupational physician 
from the seismic company did not have access to these 
results. In our experience with these oil and gas indus-
try vessels, 5% of the volunteer donors were ruled out 
through biological screening.
For the expedition cruise vessels we did not implement 
a prescreening of volunteers, since the pool of potential 
donors change almost every week with new passengers and 
also the size of the pool was much larger (400 vs. 60 in Oil 
and Gas vessels), which allowed us to have more choice in 
the qualification of volunteers.
When a life threatening bleeding occurs, and FWBT is 
needed, to qualify a unit of whole blood on site requires 
the following steps: 
 — identification of the patient blood type and obtaining 
authorisation for transfusion from the patient or his/
her relatives;
 — selecting matching volunteer blood donors: from among 
the pool of prescreened volunteers, if any, (however for-
mer volunteers could decide, whenever they wanted, to 
withdraw from the volunteering list, there was no formal 
commitment) or through a public call for donors in cruise 
vessels. For the latest we set a priority order to select 
multiple donors based on potential infectious status: 
active blood donors with up to date Donor’s Card were 
favoured, while crew who had higher risk behaviours 
(more frequent compared to the passenger population) 
or patient’s  relatives with potential bias in screening 
interview were not the preferred donors;
 — medical interview with the donor to rule out potential 
risk (medications, acute infection, risk behaviours, etc.), 
even for the prescreened volunteers;
 — blood collection and on site rapid biological control for 
HIV, hepatitis B and C and blood type;
 — blood sampling for complete a posteriori biological quali-
fication (to be conducted after shipping to the laboratory 
ashore);
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 — final bedside blood type matching between the receiver 
and the FWB pouch collected. 
The medical team was initially trained in the French 
Military Transfusion Centre, Centre de Transfusion Sanguine 
des Armées (CTSA) in Paris, which is a reference centre for 
FWBT. The team had to conduct mandatory onboard drills 
to practice the complex procedure for FWB collection which 
only gives 70–90 min to have the first 0.5 L pouch of FWB 
qualified for transfusion. 
The FWB units, as regulated by the French Joint Military 
Health Service in Instruction No. 509396/DEF/DCSSA/PC/ 
/BMA [6] can be stored at room temperature for 6 h and 
for 48 h at +2/+6°C.
In order to manage the golden hour, waiting for the first 
unit of FWB to be collected and qualified, the medical team 
could rely on lyophilised plasma, a universal freeze dried 
plasma produced by CTSA and which requires less than 
6 min [7] to get prepared (sterile water is mixed with dry 
plasma powder) and can help manage the initial hypovo-
laemia and coagulopathy. This product is perfectly adapted 
to austere environment it has a 2 year shelf life at room 
temperature, and is universally used for any blood type. 
Finally a specific hot line providing 24/7 medical advice on 
FWBT, run by specialists in emergency blood transfusion 
from CTSA, was available, in complement to the standard 
24/7 maritime medical top side support.
CONCLUSIONS
Managing autonomously a severe patient for hours or 
days require a very significant upgrade of medical resources. 
Health Authorities, Flag regulations, Company Policies rarely 
address such extreme medical conditions. Ethic and laws 
require for ship owners and company staff, to implement 
mitigation measures adapted to the risks. Nowadays, the 
available technology make these upgrades feasible and 
affordable, especially when life is at stake or more trivial-
ly operations are in balance. The authors demonstrated 
through 3 years of medical support of polar seismic surveys 
and polar expedition cruises that these upgrades are ethi-
cally, technically, and economically sound. 
Seafarers and cruise passengers deserve a level of care 
as close as the standards they receive at home. Deployment 
of FWBT and lyophilised plasma help reduce the gap be-
tween the level of care ashore and in a remote environment 
with regard to bleeding management.
Potentially, pooling these medical resources between 
different operators sailing in the same area, through “re-
gional medical coordination” would make sense from an 
economic point of view but also technically. Indeed, pool-
ing volunteer blood donors from a larger group of people 
increase the probability of getting the right blood type for 
the casualty when he/she carries a rare blood type.
Finally, in some remote areas of the world such a med-
ical facility might be the best equipped hospital also for 
the local population and may be an asset which could be 
generously shared with the ones in great need.
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